.ANALYSIS HIGHLIGHT.16 Oct 2024. In the NIAGARA trial, the addition of perioperative durvalumab to common procedure for muscle-invasive bladder cancer improved event-free and also on the whole survival, noting a brand new therapy choice for this problem.